NCT04415346Unknown1 期
A Single Center, Phase I Clinical Trial to Evaluate the Safety of LIZTOX Inj in the Treatment of Post Stroke Upper Limb Spasticity
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 13
- 试验地点
- 2
- 主要终点
- MAS score improvement at Wrist Flexor, Elbow Flexor, Finger Flexor
研究概览
简要总结
- Investigational Product: LIZTOX inj 100unit(HU-014)
- Title : A Single Center, Phase I Clinical Trial to Evaluate the Safety of LIZTOX Inj in the Treatment of Post Stroke Upper Limb Spasticity
- Sites and investigators : Asan Medical Center(Seoul), Min-ho Chun, M.D, Ph.D
- Objective : To evaluate the safety of LIZTOX inj in the treatment of Post Stroke Upper Limb Spasticity
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A subject who is diagnosed with Stroke at least six weeks prior to Screening.
- •A subject who has Modified ashworth scale(MAS) score which Wrist Flexor is ≥ 2 and Flexor or Finger Flexor is ≥
- •A subject with a Disability assessment scale(DAS)of at least ≥ 2 in one of the categories of hand hygiene, clothing, upper extremity, or pain for evaluation.
排除标准
- •A subject who has medical history following. (Allergy, Chemodenervation(within 6 months), Tendon lengthening(within 6 months), Intrathecal baclofen.Aspiration pneumonia, etc.)
- •A subject who has history of any diseases following. (neuromuscular junction disorder, NMJ, myasthemia gravis, MG, Lambert-Eaton myasthenic syndrome, amyotrophic lateral sclerosis, ALS, Skin disease, Dysphagia, etc.)
- •From screening, Subject who get a plastic Surgery including fascioplasty, Prosthesis implantation within 6 Weeks
- •Subject who takes a medication including skeletal muscle relaxants, Aminoglycoside, lincomycin, anticholinergic drug, benzodiazepine, benzamide etc.
- •A subject who tend to bleed or are taking anti-coagulant drugs.
- •A sugject who is undergoing rehabilitation(physical therapy, occupational therapy, exercise therapy) or Splinting in the area where medication for clinical trials is scheduled to be administered.
- •A sugject who has muscle atrophy, fixed joint/muscle contracture in the area where medication for clinical trials is scheduled to be administered.
- •Any condition that, in the view of the investigator, would interfere with study participation.
结局指标
主要结局
MAS score improvement at Wrist Flexor, Elbow Flexor, Finger Flexor
时间窗: Week 4, 8, 12 from baseline visit(=Investigational product Injection)
The rate of change in muscle tension measured by MAS
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate Safety and PK Profiles of OLX10010 in Healthy SubjectsCicatrix, HypertrophicNCT03569267Olix Pharmaceuticals, Inc.48
Unknown
不适用
CETO First in Human TrialPrimary AldosteronismNCT04529018University of Cambridge11
已完成
1 期
Assessment of Safety, Tolerability and PK Profile of MSP008-22 in Patients With Advanced Solid TumoursAdvanced Solid TumorNCT05478486Godavari Biorefineries Limited7
Unknown
1 期
A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor TreatmentNon-small Cell Lung CancerNCT04872634NKMAX Co., Ltd.24
已完成
1 期
Clinical Study of 68Ga-LNC1007 Injection PET/CTHealthy VolunteersCancer PatientsNCT06463782Yantai LNC Biotechnology Singapore PTE. LTD.8